Market Overview:
Meropenem is a carbapenem antibiotic, which is active against gram-positive and gram-negative bacteria. Meropenem penetrate bacterial cells by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem injection does not work for cold, flu or other viral infections. Taking antibiotics when they are not needed increases the risk of getting an infection which afterwards resists antibiotic treatment. Meropenem is an important option for the empirical treatment of serious bacterial infections in hospitalized patients.
Attributes | Details |
---|
Study Period | 2018-2028 |
Base Year | 2022 |
Forecast Period | 2023-2028 |
Historical Period | 2018-2022 |
Unit | Value (USD Million) |
Key Companies Profiled | Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility |
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Key Players of Meropenem Market Study:
Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Fresenius Kabi (Canada), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Abbott (United States) and GE Healthcare (United States)
Meropenem Market Segment Analysis
Scope | Sub-Segments |
---|
Application / End User | Skin and Skin Structure Infection, Intra-abdominal infection, Meningitis, Nosocomial Infection and Others |
End Users | Adult,Pediatric |
Distribution Channel | Online,Offline |
Strength | 0.5g,1.0g,1.5g,2.0g |
Influencing Trend:
Growing use in empirical treatment and Effective in the treatment of bacterial meningitis
Market Growth Drivers:
Increasing awareness towards healthy lifestyle and Rising prevalence of skin infection across the globe
Challenges:
Easy availability of substitutes
Restraints:
Inappropriate use can affects adversely
Opportunities:
Increasing healthcare infrastructure in developing countries
Some of the other players that are also part of study are Spectrum Chemical Manufacturing Corp (United States), Shijiazhuang Pharma (China) and Haikou Pharmaceutical Factory (China). The Global Meropenem market is gaining huge competition due to involvement of Chinese and Japanese companies that constantly invest in research & development to meet market expectation with new innovation.
March 20, 2019: Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics and On 7th Jan 2019 Takeda has acquired Shire
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Meropenem market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Meropenem market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the reports scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of pharmaceutical drugs, Suppliers of pharmaceutical drugs, Wholesalers, distributers and retailers of pharmaceutical drugs, Healthcare industry, Research Firms and Governmental bodies.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.